Products
Platform
Research
Market
Learn
Compare DSP Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.92 | 1.87 |
NAV | ₹39.79 | ₹40.50 |
Fund Started | 12 Nov 2018 | 25 Jun 2018 |
Fund Size | ₹3106.92 Cr | ₹6161.81 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.92
1.87
NAV
₹39.79
₹40.50
Fund Started
12 Nov 2018
25 Jun 2018
Fund Size
₹3106.92 Cr
₹6161.81 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | -1.62% | 4.46% |
3 Year | 23.74% | 28.36% |
5 Year | 19.14% | 21.77% |
1 Year
-1.62%
4.46%
3 Year
23.74%
28.36%
5 Year
19.14%
21.77%
Holding Analysis
Equity | 97.15% | 95.88% |
Cash | 2.85% | 4.12% |
Equity
97.15%
95.88%
Cash
2.85%
4.12%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Cipla Ltd. | 9.16% |
Sun Pharmaceutical Industries Ltd. | 7.88% |
Ipca Laboratories Ltd. | 7.56% |
Cohance Lifesciences Ltd. | 7.38% |
Laurus Labs Ltd. | 6.12% |
Gland Pharma Ltd. | 5.55% |
Apollo Hospitals Enterprise Ltd. | 4.77% |
Globus Medical Inc | 4.66% |
Illumina Inc. (USA) | 4.53% |
Sai Life Sciences Ltd. | 4.52% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.71% |
Dr. Reddy's Laboratories Ltd. | 9.47% |
Divi's Laboratories Ltd. | 9.23% |
Cipla Ltd. | 7.39% |
Aurobindo Pharma Ltd. | 6.53% |
Lupin Ltd. | 5.44% |
Alkem Laboratories Ltd. | 4.00% |
Mankind Pharma Ltd. | 3.50% |
Biocon Ltd. | 3.21% |
Gland Pharma Ltd. | 2.88% |
Fund Manager
Name | Jay Kothari | Dharmesh Kakkad |
Start Date | 16 Mar 2018 | 23 Feb 2021 |
Name
Jay Kothari
Dharmesh Kakkad
Start Date
16 Mar 2018
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 12 Nov 2018 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
12 Nov 2018
25 Jun 2018
